Cargando…

Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques

BACKGROUND: Neoadjuvant chemotherapy (NACT) is widely used as an efficient breast cancer treatment. Ideally, a pathological complete response (pCR) can be achieved. Up to date, there is no reliable way of predicting a pCR. For the first time, we explore the ability of minimal invasive biopsy (MIB) t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heil, Joerg, Kümmel, Sherko, Schaefgen, Benedikt, Paepke, Stefan, Thomssen, Christoph, Rauch, Geraldine, Ataseven, Beyhan, Große, Regina, Dreesmann, Volker, Kühn, Thorsten, Loibl, Sibylle, Blohmer, Jens-Uwe, von Minckwitz, Gunter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705891/ https://www.ncbi.nlm.nih.gov/pubmed/26554654 http://dx.doi.org/10.1038/bjc.2015.381

Ejemplares similares

Is Breast Surgery Necessary for Breast Carcinoma in Complete Remission Following Neoadjuvant Chemotherapy?
por: Richter, Hannah, et al.
Publicado: (2018)

Impact of Nuclear Oestrogen Receptor Beta Expression in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
por: Heitz, Florian, et al.
Publicado: (2019)

Outcome after neoadjuvant chemotherapy in elderly breast cancer patients – a pooled analysis of individual patient data from eight prospectively randomized controlled trials
por: von Waldenfels, Gabriel, et al.
Publicado: (2018)

RESPONDER – diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial
por: Heil, Joerg, et al.
Publicado: (2018)

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy
por: Darb-Esfahani, Silvia, et al.
Publicado: (2016)

Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy
por: Sinn, Bruno Valentin, et al.
Publicado: (2019)

Neutrophil Gelatinase-Associated Lipocalin (NGAL) Predicts Response to Neoadjuvant Chemotherapy and Clinical Outcome in Primary Human Breast Cancer
por: Wenners, Antonia Sophie, et al.
Publicado: (2012)

Vacuum-Assisted Breast Biopsy After Neoadjuvant Systemic Treatment for Reliable Exclusion of Residual Cancer in Breast Cancer Patients
por: Koelbel, Vivian, et al.
Publicado: (2021)

Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials
por: Loibl, Sibylle, et al.
Publicado: (2008)

Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial
por: Gerber, Bernd, et al.
Publicado: (2022)

Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer – A Substudy of the Neoadjuvant GeparQuinto Trial
por: Issa-Nummer, Yasmin, et al.
Publicado: (2013)

Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes
por: Darb-Esfahani, Silvia, et al.
Publicado: (2014)

The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy
por: Wimberger, Pauline, et al.
Publicado: (2023)

PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane–Based Neoadjuvant Chemotherapy
por: Guo, Sanxing, et al.
Publicado: (2020)

EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy
por: Leichsenring, Jonas, et al.
Publicado: (2022)

Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast
por: von Minckwitz, Gunter, et al.
Publicado: (2008)

Tumor-infiltrating lymphocytes in breast cancer: A new predictor for responses to therapy
por: Issa-Nummer, Yasmin, et al.
Publicado: (2014)

Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy
por: Darb-Esfahani, Silvia, et al.
Publicado: (2009)

Axillary Staging after Neoadjuvant Chemotherapy for Initially Node-Positive Breast Carcinoma in Germany: Initial Data from the AXSANA study
por: Hartmann, Steffi, et al.
Publicado: (2022)

AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update
por: Friedrich, Michael, et al.
Publicado: (2021)

Correction: AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update
por: Friedrich, Michael, et al.
Publicado: (2021)

Adjuvant Docetaxel in Node-Negative Breast Cancer Patients: A Randomized Trial of AGO-Breast Study Group, German Breast Group, and EORTC-Pathobiology Group
por: Thomssen, Christoph, et al.
Publicado: (2023)

State of the art in neoadjuvant therapy of breast cancer
por: Minckwitz, Gunter von, et al.
Publicado: (2013)

Hypoglossal acupuncture for acute chemotherapy-induced dysgeusia in patients with breast cancer: study protocol of a randomized, sham-controlled trial
por: Haller, Heidemarie, et al.
Publicado: (2019)

Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto
por: Laakmann, Elena, et al.
Publicado: (2019)

Patient-reported outcomes for the Intergroup Sentinel Mamma study (INSEMA): A randomised trial with persistent impact of axillary surgery on arm and breast symptoms in patients with early breast cancer
por: Reimer, Toralf, et al.
Publicado: (2022)

FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients
por: Fasching, Peter A, et al.
Publicado: (2014)

Recent advances in systemic therapy. Advances in neoadjuvant (primary) systemic therapy with cytotoxic agents
por: Untch, Michael, et al.
Publicado: (2009)

Prognostic and predictive impact of gene expression in node‐positive early breast cancer patients receiving dose‐dense versus standard‐dose adjuvant chemotherapy
por: Reinisch, Mattea, et al.
Publicado: (2023)

Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: Phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6 × FEC versus 3 × FEC/3 × Docetaxel
por: Kantelhardt, Eva J, et al.
Publicado: (2011)

Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis
por: Loibl, Sibylle, et al.
Publicado: (2011)

A systematic review and meta-analysis on the effect of neoadjuvant chemotherapy on complications following immediate breast reconstruction
por: Varghese, Jajini, et al.
Publicado: (2020)

Gene signatures in patients with early breast cancer and relapse despite pathologic complete response
por: Bruzas, Simona, et al.
Publicado: (2022)

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer
por: Denkert, Carsten, et al.
Publicado: (2013)

Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy
por: Huober, Jens, et al.
Publicado: (2023)

Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC
por: Massa, Chiara, et al.
Publicado: (2020)

Analyzing non-sentinel axillary metastases in patients with T3–T4 cN0 early breast cancer and tumor-involved sentinel lymph nodes undergoing breast-conserving therapy or mastectomy
por: Riedel, Fabian, et al.
Publicado: (2020)

Ioncopy: a novel method for calling copy number alterations in amplicon sequencing data including significance assessment
por: Budczies, Jan, et al.
Publicado: (2016)

Reply to Comment on ‘Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques'
por: Heil, Joerg
Publicado: (2016)

First proof-of-concept evaluation of the FUSION-X-US-II prototype for the performance of automated breast ultrasound in healthy volunteers
por: Schaefgen, Benedikt, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bo7plai2bn2u52bsloiemdmmoh